The Latest Breaking News from AstraZeneca

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion.

Among the top stocks to watch, pharmaceutical leader AstraZeneca is retaking its latest buy point despite Tuesday's stock market weakness.

Public Health Minister Anutin Charnvirakul does not expect a sudden influx of Chinese tourists or see a need for any special arrival rules for them.

Former federal MP Dr Kerryn Phelps has talked this week about the medical problems she and her wife had after their COVID-19 vaccinations around 18 months ago.

SEOUL: A South Korean company is looking for a business opportunity with partners from the Association of Southeast Asian Nations (Asean) to help develop the regional market for its Covid-19 vaccine.

Sir Pascal Soriot was speaking after he was knighted by the King at Windsor Castle on Wednesday.

AstraZeneca is breaking out on the strength of its relative strength highs and as profits continue to grow.

Capivasertib is being made by pharmaceutical giant AstraZeneca following a programme of drug discovery research at the Institute of Cancer Research.

‘The treatment is far less debilitating than chemotherapy and I’ve been given the gift of a longer life,’ says one patient

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.